Neumora stock recovers to pre-KOASTAL-1 levels by end of 2025? | Binary | | | 7 days ago | |
Neumora's next major strategic move by end of 2025 | Categorical | | | 7 days ago | |
Navacaprant shows efficacy in women in KOASTAL-2 or KOASTAL-3 by end of 2025? | Binary | | | 7 days ago | |
Neumora discontinues navacaprant development by end of 2025? | Binary | | | 7 days ago | |
Outcome of KOASTAL-2 Phase 3 trial for navacaprant by end of 2025 | Categorical | | | 7 days ago | |
Next major competitor to launch KOR antagonist drug by end of 2025 | Categorical | | | 7 days ago | |
Will Neumora announce a new strategic direction or partnership by March 2025? | Binary | | | 7 days ago | |
Will Neumora present new KOASTAL-1 analysis at J.P. Morgan Healthcare Conference by January 2025? | Binary | | | 7 days ago | |
Will Neumora shares recover to half of pre-KOASTAL-1 value by June 2025? | Binary | | | 7 days ago | |
What will be the outcome of Neumora's KOASTAL-2 trial by end of 2025? | Categorical | | | 7 days ago | |
What will be Neumora's cash runway status by June 2025? | Categorical | | | 7 days ago | |
How will Neumora's shares respond to KOASTAL-3 results by end of 2025? | Categorical | | | 7 days ago | |
